145 related articles for article (PubMed ID: 34220957)
1. A Novel Prognostic Biomarker of Luminal Breast Cancer: High CD39 Expression Is Related to Poor Survival.
Ni X; Wan W; Ma J; Liu X; Zheng B; He Z; Yang W; Huang L
Front Genet; 2021; 12():682503. PubMed ID: 34220957
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of KLRB1 and its further association with immune cells in breast cancer.
Xu N; Meng X; Chu H; Yang Z; Jiao Y; Li Y
PeerJ; 2023; 11():e15654. PubMed ID: 37520246
[TBL] [Abstract][Full Text] [Related]
3. Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates.
Fang Y; Liu J; Zhang Q; She C; Zheng R; Zhang R; Chen Z; Chen C; Wu J
World J Surg Oncol; 2022 Jun; 20(1):211. PubMed ID: 35729567
[TBL] [Abstract][Full Text] [Related]
4. Identification of Tumor Microenvironment-Related Prognostic Biomarkers in Luminal Breast Cancer.
Wang Y; Zhu M; Guo F; Song Y; Fan X; Qin G
Front Genet; 2020; 11():555865. PubMed ID: 33329695
[No Abstract] [Full Text] [Related]
5. The Analysis of PTPN6 for Bladder Cancer: An Exploratory Study Based on TCGA.
Shen C; Liu J; Wang J; Yang X; Niu H; Wang Y
Dis Markers; 2020; 2020():4312629. PubMed ID: 32454905
[No Abstract] [Full Text] [Related]
6. A new prognostic factor of breast cancer: High carboxyl ester lipase expression related to poor survival.
Cui Y; Jiao Y; Wang K; He M; Yang Z
Cancer Genet; 2019 Nov; 239():54-61. PubMed ID: 31561066
[TBL] [Abstract][Full Text] [Related]
7. Cysteine conjugate beta-lyase 2 (CCBL2) expression as a prognostic marker of survival in breast cancer patients.
Meng X; Wang L; He M; Yang Z; Jiao Y; Hu Y; Wang K
PLoS One; 2022; 17(6):e0269998. PubMed ID: 35771747
[TBL] [Abstract][Full Text] [Related]
8. Reduced Expression of KRT17 Predicts Poor Prognosis in HER2
Tang S; Liu W; Yong L; Liu D; Lin X; Huang Y; Wang H; Cai F
Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139022
[TBL] [Abstract][Full Text] [Related]
9. HSPB8 is a Potential Prognostic Biomarker that Correlates With Immune Cell Infiltration in Bladder Cancer.
Tan Z; Fu S; Huang Y; Duan X; Zuo Y; Zhu X; Wang H; Wang J
Front Genet; 2022; 13():804858. PubMed ID: 35330734
[No Abstract] [Full Text] [Related]
10. Overexpression of
Lyu L; Wang M; Zheng Y; Tian T; Deng Y; Xu P; Lin S; Yang S; Zhou L; Hao Q; Wu Y; Dai Z; Kang H
Cancer Manag Res; 2020; 12():12457-12471. PubMed ID: 33299353
[TBL] [Abstract][Full Text] [Related]
11. MRPL13 is a Prognostic Cancer Biomarker and Correlates with Immune Infiltrates in Breast Cancer.
Tao Z; Suo H; Zhang L; Jin Z; Wang Z; Wang D; Wu M; Peng N; Zhao Y; Chen B
Onco Targets Ther; 2020; 13():12255-12268. PubMed ID: 33273831
[TBL] [Abstract][Full Text] [Related]
12. Exploration of the immune-related signature and immune infiltration analysis for breast ductal and lobular carcinoma.
Zhang B; Wang Q; Fu C; Jiang C; Ma S
Ann Transl Med; 2019 Dec; 7(23):730. PubMed ID: 32042746
[TBL] [Abstract][Full Text] [Related]
13. In lung adenocarcinoma, low expression of the cell surface extracellular nucleotidase CD39 is related to immune infiltration and a poor prognosis.
Shao L; Wang X; Yu Q; Gong J; Zhang X; Zhou Y
J Thorac Dis; 2022 Dec; 14(12):4938-4950. PubMed ID: 36647506
[TBL] [Abstract][Full Text] [Related]
14. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
15. A Novel Immune and Stroma Related Prognostic Marker for Invasive Breast Cancer in Tumor Microenvironment: A TCGA Based Study.
Huang Y; Chen L; Tang Z; Min Y; Yu W; Yang G; Zhang L
Front Endocrinol (Lausanne); 2021; 12():774244. PubMed ID: 34867821
[TBL] [Abstract][Full Text] [Related]
16. Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer.
Tang W; Xu F; Zhao M; Zhang S
BMC Cancer; 2021 Oct; 21(1):1160. PubMed ID: 34715817
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating CD39
Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Analysis of Regulatory Factors and Immune-Associated Patterns to Decipher Common and
Li Y; Dong W; Zhang P; Zhang T; Ma L; Qu M; Ma X; Zhou X; He Q
Front Cell Dev Biol; 2021; 9():750897. PubMed ID: 34733851
[No Abstract] [Full Text] [Related]
19. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value and association with epithelial-mesenchymal transition and molecular subtypes of the proteoglycan biglycan in advanced bladder cancer.
Schulz GB; Grimm T; Sers C; Riemer P; Elmasry M; Kirchner T; Stief CG; Karl A; Horst D
Urol Oncol; 2019 Aug; 37(8):530.e9-530.e18. PubMed ID: 31176613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
